Dermatitis

Recruiting

Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis

This is a multicenter, randomized, double-blind, placebo-controlled, 2-arm, parallel-group study that will investigate the efficacy and safety of mepolizumab SC in adolescent and adult subjects with moderate to severe AD.

Status

Recruiting

Closed for Recruitment

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

This is an open label extension study for patients who participated in placebo-controlled dupilumab atopic dermatitis (AD) trials. The study primarily evaluates long term safety (adverse events) and immunogenicity. Efficacy parameters are based on Investigator Global Assessment (IGA), Eczema Area and Severity Index (EASI) and the Pruritus Numerical Rating Scale (NRS).

Status

Closed for Recruitment

Subscribe to Dermatitis